Press Releases
Excerpt from the Press Release: When startup TFF Pharmaceuticals raised $14 million in a series A in 2018, its intention was to deploy its dry-powder drug-delivery technology toward making novel inhalable therapies for asthma, chronic obstructive pulmonary disease and other serious lung diseases. Then COVID-19 hit, and the company saw an opportunity to apply the…
Read More
— Recommendation is Based on the Phase 3 ASCENT Study Showing that Sacituzumab Govitecan Significantly Improved Overall Survival in 2L vs. Physician’s Choice of Chemotherapy in Metastatic Triple-Negative Breast Cancer — — Sacituzumab Govitecan Could Offer a New Treatment Option for an Aggressive Type of Metastatic Breast Cancer if Approved — Excerpt from the Press…
Read More
Excerpt from the Press Release: BRISBANE, Calif. – October 7, 2021 – Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented preclinical data demonstrating that the Company’s novel microbiome-derived peptide, SG-3-0020, can upregulate key co-stimulatory and checkpoint molecules on T cells. The data (poster P260)…
Read More
Presentations highlight potential of the oral MDM2 inhibitor, milademetan, in advanced cancers with MDM2 amplification, GATA3 mutant ER-positive breast cancer, and Merkel cell carcinoma Excerpt from the Press Release: NEWARK, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) — Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced data on its…
Read More
-Preclinical findings that demonstrated efficacy in non-small cell lung cancer (NSCLC) driven by RAS or other MAPK-pathway activating mutations will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -BridgeBio’s SHP2 inhibitor, BBP-398, is part of its growing precision oncology portfolio, which also includes KRAS inhibitors for KRAS cancers, GPX4 inhibitors…
Read More
– AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment of patients with solid tumors. – The collective preclinical data indicate that AMX-818 is effective in driving anti-tumor responses, yet has significantly lower toxicity than its unmasked HER2 TCE counterpart. This…
Read More
– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5 in Phase 1 dose escalation in unselected patients – – CDK9 inhibitor PRT2527 demonstrates strong efficacy in hematological malignancies and solid tumor models with MYC dysregulation in preclinical studies…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass., Oct. 7, 2021 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new data with PH-894, Phio’s self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) at the AACR-NCI-EORTC Virtual International Conference on Molecular…
Read More
Preclinical data demonstrate that XMT-2056 activates the STING pathway in a target-dependent manner in both tumor cells and tumor-resident immune cells and is significantly more efficacious in head-to-head studies than trastuzumab-TLR7/8 agonist ADC and small-molecule systemically-administered STING agonist benchmarks XMT-2056 targets a novel epitope of HER2 with differentiated binding from trastuzumab and pertuzumab, potentially allowing…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical data for CA-4948, a first-in-class small molecule IRAK4 inhibitor, at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics.…
Read More